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Objective: To determine the effects of high molecular weight hyaluronic acid (HMW-HA) on osteoclast
differentiation by monocytes co-cultured with stromal cells.
Methods: Mouse bone marrow stromal cell line ST2 cells were incubated with HMW-HA or 4-
methylunbeliferone (4-MU) for various times. In some experiments, cells were pre-treated with the
anti-CD44 monoclonal antibody (CD44 mAb) or Rho kinase pathway inhibitors (simvastatin or Y27632),
then treated with HMW-HA. The expression of receptor activator of NF-kB ligand (RANKL) was deter-
mined using real-time reverse transcription polymerase chain reaction (RT-PCR), western blotting, and
immunoﬂuorescence microscopy, while the amount of active RhoA was measured by a pull-down assay.
To further clarify the role of HMW-HA in osteoclastogenesis, mouse monocyte RAW 264.7 cells were co-
cultured with ST2 cells pre-stimulated with 1,25(OH)2D3. Osteoclast-like cells were detected by staining
with tartrate-resistant acid phosphatase (TRAP).
Results: HMW-HA decreased RANKL mRNA and protein expressions, whereas inhibition of hyaluronic
acid (HA) synthesis by 4-MU enhanced RANKL expression. Blockage of HA-CD44 binding by CD44 mAb
suppressed HMW-HA-mediated inhibition of RANKL. Pull-down assay ﬁndings also revealed that HMW-
HA transiently activated RhoA in ST2 cells and pre-treatment with CD44 mAb inhibited the activation of
RhoA protein mediated by HMW-HA. Moreover pre-treatment with Rho kinase pathway inhibitors also
blocked the inhibition of RANKL by HMW-HA. Co-culture system results showed that HMW-HA down-
regulated differentiation into osteoclast-like cells by RAW 264.7 cells induced by 1,25(OH)2D3-stimulated
ST2 cells.
Conclusions: These results indicated that HA-CD44 interactions down-regulate RANKL expression and
osteoclastogenesis via activation of the Rho kinase pathway.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Hyaluronan, or hyaluronic acid (HA), is an unsulfated long
polysaccharide chain comprised of repeating disaccharide units of
N-acetylglucosamine and glucuronic acid, and a major component
of the extracellular matrix (ECM). HA is present with a high mo-
lecular mass inmammalian bonemarrow and connective tissues, as
well as skin, vitreous humor of the eye, cartilage, and umbilical cord
tissue. Unlike other glycosaminoglycans, it is synthesized as a free. Nishihara, 2-6-1 Manazuru,
3-285-3050; Fax: 81-93-581-
iyoshi), t-oki@kyu-dent.ac.jp
dson), knudsonw@ecu.edu
s Research Society International. Ppolysaccharide, rather than substituted on a core protein, and
newly synthesized HA polymers of 2,500e25,000 repeating di-
saccharides have a molecular mass ranging from 103e104 kDa. The
roles of HA range from purely structural functions to regulation of
several cellular responses including proliferation, differentiation,
motility, adhesion and gene expression.1,2
High molecular weight hyaluronic acid (HMW-HA) is clinically
used as a symptom- or disease-modifying drug for non-surgical
treatments of joints as well as cartilage diseases such as osteoar-
thritis (OA)3, as the efﬁcacy of articular HA therapy for OA has been
demonstrated in animal experimental models4,5 and clinical tri-
als6,7. Although the underlying mechanisms may be due to its
chondroprotective and anti-inﬂammatory effects, the precise roles
of HA in the pathogenesis of OA remain largely unknown.
Many connective tissue cells exhibit a large HA and
proteoglycan-rich pericellular matrix that is tethered to the cell
surface via interactions with the HA receptor CD448, aublished by Elsevier Ltd. All rights reserved.
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sive molecular heterogeneity. The CD44 ectodomain is responsible
for the binding of HA, while the cytoplasmic domain regulates
speciﬁc signaling such as RhoA-activated Rho kinase9, Rho/Rac1-
speciﬁc guanine nucleotide exchange factors (p115RhoGEF10,
Tiam111, and Vav212), c-Src kinase13, and transforming growth
factor-b receptors14. CD44 also directly binds to cytoskeletal pro-
teins such as ankyrin and ERM (ezrin, radixin, moesin).15
Bone remodeling is a highly regulated process involving the
coordinated action of osteoblasts and osteoclasts. Osteoclasts
originate from hematopoietic precursors of a monocyte/macro-
phage lineage and differentiate into multinucleated giant cells
specialized to resorb bone by fusion of mononuclear progenitors16.
It has also been shown that osteoclast precursors must interact
with osteoblasts/stromal cells to differentiate into mature osteo-
clasts17, while osteoclast formation is induced in the presence of the
receptor activator of the NF-kB ligand (RANKL), a member of the
tumor necrosis factor (TNF) superfamily, which is expressed by
osteoblasts/bone stromal cells. RANKL interacts with the osteoclast
cell surface receptor RANK, which in turn recruits TNF receptor-
associated factors (TRAFs)18, and plays a crucial role in the osteo-
clast differentiation axis.
It is possible that receptor-mediated effects of HA and de-
rivatives lead to changes in the metabolism of chondrocytes19,20,
synoviocytes21,22, and subchondral bone osteoblasts23, and
several researchers have reported the involvement of HA in
osteoclast formation and resorption24,25. In a previous study, we
demonstrated that low molecular weight HA (LMW-HA, molec-
ular weight <8 kDa) enhanced both osteoclast formation and
function in vitro26. However, scant attention has been given to the
effects of HMW-HA on osteoclast-supporting cells. In the present
study, we examined the effects of HMW-HA on osteoclasto-
genesis and found that it suppressed osteoclast formation via
down-regulation of RANKL in bone marrow derived osteoblastic/
stromal cells in vitro.Methods
Reagents and antibodies
High molecular weight HA (HMW-HA, molecular weight
2,500 kDa) was supplied by Seikagaku Corp. (Tokyo, Japan), while
4-methylumberlliferone (4-MU) was purchased from Sigmae
Aldrich (St. Louis, MO, USA). The anti-RANKL polyclonal antibody
was obtained from R&D Systems Inc. (Minneapolis, MN, USA), anti-
b-actin monoclonal antibody from SigmaeAldrich and anti-RhoA
monoclonal antibody from Cell Signaling Technology Inc. (Bev-
erly, MA, USA).Cell cultures
Mouse bone marrow stromal cells ST2 was obtained from Riken
Cell Bank (Ibaraki, Japan) and maintained in alpha-minimum
essential medium (a-MEM; GIBCO, Grand Island, NY, USA) sup-
plemented with 10% fetal calf serum (FCS; SigmaeAldrich), 100 U/
ml penicillin G (Meiji Seika Pharm Co., Tokyo, Japan), and 100 mg/ml
streptomycin (Wako Pure Chemical Industries, Osaka, Japan) at
37C in an atmosphere of 5% CO2. ST2 cells were incubated with
HMW-HA or 4-MU for various times. For some experiments, cells
were pre-treated with the anti-CD44 monoclonal antibody (10 mg/
ml, Calbiochem, San Diego, CA, USA), simvastatin (10 mM, Sigmae
Aldrich), or Y27632 (10 mM, Calbiochem), then treated with HMW-
HA (50 mg/ml) in the continuing presence or absence of each
reagent.Detection of cell surface HA and RANKL
ST2 cells were treated in 8-well chamber slides (5  103 cells/
well), then ﬁxed with 4% paraformaldehyde in phosphate buffered
saline (PBS, pH 7.4) for 1 h, quenched with 0.2 M glycine in PBS, and
blocked with 1% bovine serum albumin (BSA, SigmaeAldrich) in
PBS for 1 h. For HA detection, the cells were incubated with 2.0 mg/
ml of a biotinylated-HA binding protein (HABP) probe (Seikagaku
Corp.) overnight at 4C. Following extensivewashing, the cells were
incubated with 1 mg/ml neutravidin-ﬂuorescein isothiocyanate
(FITC) (1:1,000) (Invitrogen, Carlsbad, CA, USA) in PBS containing
1% BSA for 1 h at 4C.
For immunoﬂuorescence analysis of RANKL, ﬁxed cells were
incubated overnight with the anti-RANKL antibody (1:100), then
for 1 h at room temperature with FITC conjugated anti-goat IgG
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). To visualize stress
ﬁbers, cells were incubated with rhodamine phalloidin (Invitrogen)
for 20 min at room temperature, then washed, mounted in
mounting medium containing the nuclear stain, 406-diamidino-2-
phenylindole dihydrochloride (DAPI; Vector Laboratories Inc.,
Burlingame, CA, USA), and visualized using a Fluorescence Micro-
scope BZ-9000 (Keyence Corp., Osaka, Japan). Images were
captured digitally in real time and processed using BZ-II imaging
software (Keyence Corp.).Quantitative real-time reverse transcription polymerase chain
reaction (RT-PCR)
Total RNA was isolated from cells with TRIzol reagent (Invi-
trogen). Samples were reverse transcribed with q-Srcipt cDNA
Supermix reagents (Quanta BioSciences, Gaithersburg, MD, USA)
and ampliﬁed for 30 min at 42C. For real-time RT-PCR, the PCR
products were detected using FAST SYBR Green Master Mix
(Applied Biosystems, Foster City, CA, USA) using the following
primer sequences: Gapdh forward; 50-GACGGCCGCATCTTCTTGA-30
and reverse; 50-CACACCGACCTTCACCATTTT-30, and Rankl forward;
50-GGCCAC AGCGCTTCTCA-30 and reverse; 50-CCTCGCTGGGCCA-
CATC-30. Thermal cycling and ﬂuorescence detection were per-
formed using a StepOne Real-Time System (Applied Biosystems).
Real-time RT-PCR efﬁciency for each primer set was calculated
according to the method of Rasmussen et al.27 The fold increase in
copy numbers of mRNA was calculated as the relative ratio of the
Rankl gene to Gapdh, following the model of Pfafﬂ.28Western blot analysis
Following incubation, total protein was extracted using Cell
Lysis Buffer (Cell Signaling Technology) containing a protease in-
hibitor cocktail (Thermo Fisher Scientiﬁc, Waltham, MA, USA) and
protein contents were measured using a DC protein assay kit (Bio-
Rad, Hercules, CA, USA). Twenty micrograms of total protein per
sample was loaded and separated on a Mini-PROTEAN TGX 4e15%
gradient SDS-PAGE gel (Bio-Rad), then transferred onto poly-
vinylidene diﬂuoride membranes (Millipore Corp., Bedford, MA,
USA). Nonspeciﬁc binding sites were blocked by immersing the
membranes in 5% skim milk in PBS for 1 h at room temperature.
Membranes were subjected to incubation overnight with diluted
primary antibodies at 4C, followed by horseradish peroxidase
(HRP) conjugated secondary antibodies for 1 h at room tempera-
ture. After washing the membranes, chemiluminescence was pro-
duced using ECL reagent (Amersham Pharmacia Biotech, Uppsala,
Sweden) and detected digitally with a GelDoc XR Plus System
(Bio-Rad). Goat anti-RANKL and mouse anti-b-actin were used as
the primary antibodies, while HRP-conjugated anti-goat IgG (Santa
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Chalfont, UK) were used as secondary antibodies.
RhoA activity
The amount of active RhoAwas measured by using a pull-down
assay with Rho Assay Reagent (Millipore Corp.), according to the
manufacturer’s instructions. Brieﬂy, treated cells were washed
twice in ice-cold PBS and lysed in lysis buffer (125 mM HEPES pH
7.5, 750 mM NaCl, 5% Igepal CA-630, 50 mMMgCl2, 5 mM EDTA, 10
% glycerol), then the lysates were clariﬁed by centrifugation at
14,000  g for 5 min. Thereafter, the supernatant was incubated
with Rhotekin-Rho binding domain beads for 45 min with gentle
agitation at 4C, after which the beads were washed 3 times with
lysis buffer, followed by re-suspension in 40 ml of Laemmli reducing
sample buffer. Precipitated GTP-bound and total RhoA proteins
were then analyzed using western blotting analysis with an anti-
RhoA monoclonal antibody.
Osteoclast formation in co-culture system
Osteoclasts were detected by staining with tartrate-resistant
acid phosphatase (TRAP) using an Acid Phosphatase Leukocyte Kit
(SigmaeAldrich). In brief, ST2 cells (5  102 cells/well) were plated
in a 96-well plate with aMEM containing 10% FBS and 107 M
1,25(OH)2D3 (SigmaeAldrich) in the presence or absence of HMW-
HA (50 mg/ml). The next day, mouse monocyte RAW 264.7 cellsFig. 1. Effect of HMW-HA on RANKL expression in ST2 cells. ST2 cells were incubated in the
Cells were incubated with a biotinylated HABP probe and HA accumulationwas visualized us
concentration dependency (ANOVA: P < 0.0001) of Rankl mRNA stimulation by HMW-HA w
number values from independent samples of n ¼ 3, and bars represent means with the stand
indicates P < 0.0001 in comparison to control without any treatment. (D) Whole cell lysates
RANKL. Equivalent protein aliquots of cell lysates were also analyzed for b-actin.(Riken Cell Bank, Ibaraki, Japan, 1103 cells/well) were overlaid for
the co-culture system. After co-culturing for 7 days, adherent cells
were ﬁxed and stained for TRAP activity, with TRAP-positive
multinucleated cells containing three or more nuclei counted un-
der a microscope as osteoclast-like cells.
Statistics analysis
All statistics analyses were carried out using JMP software,
version 10.0.2 (SAS Institute Inc., Cary, NC, USA). Each of the data
groups was tested by using ShapiroeWilk test and considered to
follow a Gaussian distribution when the P-value was greater than
0.05. The Levene’s test of homogeneity was used to determine the
homogeneity of variance. All data were expressed as
mean  standard deviation and analyzed by one-way analysis if
variance (ANOVA) and if signiﬁcant, followed by the suitable post-
test (Dunnett’s or Tukey’s post-test).
Results
HMW-HA down-regulates RANKL expression
We examined the effects of HMW-HA on RANKL expression in
ST2 cells. The binding of HMW-HA (50 mg/ml) was monitored using
an HABP probe and time-dependent HA binding could be visualized
up to 3 h [Fig. 1(A)]. Primer sets for real-time RT-PCR ampliﬁcation
and quantiﬁcation of mouse Rankl and Gapdh were designed, andpresence or absence of HMW-HA for varying times and in various concentrations. (A)
ing neutravidin-FITC. Bars indicate 10 mm. (B) Time course (ANOVA: P < 0.0001) and (C)
as determined by real-time RT-PCR. Data shows the fold changes in Rankl mRNA copy
ard deviation. Data were analyzed by Dunnett’s test after one-way ANOVA. The asterisk
were subjected to SDS-PAGE and western blotting analyses, with the blots probed for
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for comparison of mRNA copy numbers between treated and
control cultures, which were normalized to Gapdh. After 0.5 h of
incubation with HMW-HA, there was a 26.4% decrease in Rankl
mRNA copy number as compared to the untreated control cells
[Fig. 1(B)]. This effect of HMW-HA was time-dependent, with
maximum inhibition observed at the 1-h time point (96.3% inhi-
bition). A concentration-dependent inhibition of Rankl by HMW-
HA was also shown [Fig. 1(C)], which reached a maximum at a
concentration of 50 mg/ml following 1 h of treatment (93% inhibi-
tion). As shown in [Fig. 1(D)], ST2 cell lysates from the control
cultures expressed immunoreactive RANKL protein, while treat-
ment with HMW-HA reduced RANKL protein expression in the ST2
cells for up to 48 h.
4-MU up-regulates RANKL expression
Next, we investigated whether the receptor-HA pathway has an
inﬂuence on the expression of RANKL in ST2 cells using 4-MU. It has
been reported that 4-MU inhibits HA synthesis and pericellular HA
matrix formation in cultured cells.29,30 We found a time-dependent
decrease in accumulation of endogenous HA for up to 6 h following
treatment with 4-MU (0.5 mM) [Fig. 2(A)]. Real-time RT-PCR also
revealed an 8.1-fold increase in Rankl mRNA copy number as
compared to the untreated control cells after 3 h of incubationwith
HMW-HA [Fig. 2(B)]. This effect of 4-MUwas time-dependent, with
maximum enhancement observed at the 6-h time point (12.1-foldFig. 2. Effect of 4-MU on RANKL expression in ST2 cells. ST2 cells were incubated in the pres
incubated with a biotinylated HABP probe and HA accumulation was visualized using neutra
(B) Time course (ANOVA: P < 0.0001) and (C) concentration dependency (ANOVA: P < 0.0
shows the fold changes in Rankl mRNA copy number values from independent samples of
Dunnett’s test after one-way ANOVA. The asterisk indicates P < 0.0001 in comparison to c
western blotting analyses, with the blots probed for RANKL. Equivalent protein aliquots ofincrease). In addition, 4-MU induced a concentration-dependent
stimulation of Rankl [Fig. 1(C)], with maximum stimulation
observed at a concentration of 0.5 mM at 6 h after treatment (9.5-
fold increase). Treatment with 4-MU also up-regulated RANKL
protein expression in ST2 cells for up to 48 h [Fig. 2(D)].
Changes in matrix interactions by HA affect RANKL accumulation
ST2 cells at all examined culture times exhibited a background
level of RANKL that was primarily localized on the cell surface
[Fig. 3(A)]. No immunoﬂuorescent staining was seen with the sec-
ondary antibody alone [Fig. 3(B)]. After 24 h of treatment with
HMW-HA, RANKL protein accumulationwas diminished [Fig. 3(C)].
On the other hand, after 24 h of treatment with 4-MU, RANKL levels
were substantially enhanced [Fig. 3(D)].
CD44 function-blocking monoclonal antibody reverses reduction of
RANKL expression induced by HMW-HA
To further examine the role of CD44 as an HA receptor in down-
regulation of RANKL, ST2 cells were pre-treated with the CD44
function-blocking monoclonal antibody for 2 h prior to stimulation
with HMW-HA. Treatment with the monoclonal antibody inhibited
exogenous HMW-HA binding after 1 h of incubation [Fig. 4(A)].
Also, pretreatment with the monoclonal antibody effectively
recovered the down-regulation of Rankl mRNA induced by 1 h of
treatment with HMW-HA [Fig. 4(B)]. Western blotting analysisence or absence of 4-MU for varying times and in various concentrations. (A) Cells were
vidin-FITC. Coverslips were mounted in medium containing DAPI. Bars indicate 10 mm.
001) of Rankl mRNA stimulation by 4-MU was determined by real-time RT-PCR. Data
n ¼ 3, and bars represent means with the standard deviation. Data were analyzed by
ontrol without any treatment. (D) Whole cell lysates were subjected to SDS-PAGE and
cell lysates were also analyzed for b-actin.
Fig. 3. Effect of HA accumulation on RANKL expression in ST2 cells. ST2 cells were grown on chamber slides, then incubated in the (A) absence or presence (C) of 50 mg/ml of HMW-
HA, (D) or 0.5 mM of 4-MU for 24 h. Following treatment, the cells were ﬁxed and immunostained using a polyclonal antibody to detect RANKL and rhodamine isothiocyanate-
phalloidin. Coverslips were mounted in medium containing DAPI. (B) Control cells incubated with the secondary antibody alone. Shown are digital overlay images of red, green, and
blue ﬂuorescence channels. Bars indicate 20 mm.
Fig. 4. Effects of CD44 function-blocking antibody on RANKL expression regulated by HMW-HA. ST2 cells were pretreated with or without 10 mg/ml of the CD44 function-blocking
monoclonal antibody (CD44 mAb) for 2 h, then incubated in the presence or absence of HMW-HA (50 mg/ml) for the indicated time periods. (A) Cells were incubated with a
biotinylated HABP probe and HA accumulation was visualized using neutravidin-FITC. Coverslips were mounted in medium containing DAPI. Bars indicate 10 mm. (B) Total RNA was
isolated, and reverse transcribed into cDNA, then PCR ampliﬁcation was performed using primers speciﬁc for Rankl and Gapdh. Data shows the fold changes in Rankl mRNA copy
number values from independent samples of n ¼ 3, and bars represent means with the standard deviation. Data were analyzed by Tukey’s post-test after one-way ANOVA
(P < 0.0001). The asterisk indicates P < 0.0001 in comparison to treatment with HMW-HA. (C) Whole cell lysates were subjected to SDS-PAGE and western blotting analyses, with
the blots probed for RANKL. Equivalent protein aliquots of cell lysates were also analyzed for b-actin.
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Fig. 6. Effects of RhoA/ROK inhibitors on RANKL expression regulated by HMW-HA.
ST2 cells were pretreated with simvastatin (10 mM) or Y27632 (10 mM) for 24 h,
then incubated in the presence or absence of HMW-HA (50 mg/ml) for the indicated
time periods. (A) Total RNA was isolated, and reverse transcribed into cDNA, then PCR
ampliﬁcation was performed using primers speciﬁc for Rankl and Gapdh. Data shows
the fold changes in Rankl mRNA copy number values from independent samples of
n ¼ 3, and bars represent means with the standard deviation. Data were analyzed by
Tukey’s post-test after one-way ANOVA (P < 0.0001). The asterisk indicate P < 0.0001
in comparison to treatment with HMW-HA. (B) Whole cell lysates were subjected to
SDS-PAGE and western blotting analyses, with the blots probed for RANKL. Equivalent
protein aliquots of cell lysates were also analyzed for b-actin.
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regulation of RANKL protein expression mediated after 24 h of in-
cubation with HMW-HA [Fig. 4(C)].
Interaction between HMW-HA and CD44 induces sequential
activation of RhoA protein
Recent ﬁndings indicate that the Rho kinase pathway has
important roles in bone metabolism.31e33 Therefore, we next
examined whether HMW-HA induces RhoA activation in ST2 cells.
RhoA activity was assessed by detecting GTP-loaded forms of the
protein using a pull-down assay. As shown in [Fig. 5(A)], HMW-HA
transiently activated RhoA in ST2 cells from 15 to 60 min, while
RhoA activity returned to the basal level at 120 min of HMW-HA
stimulation. Pre-treatment with the CD44 function-blocking
monoclonal antibody inhibited the activation of RhoA protein
mediated by HMW-HA stimulation for 30 min [Fig. 5(B)].
Rho/ROCK inhibitors attenuate down-regulation of RANKL
expression mediated by HMW-HA
To further examine the role of RhoA activation in HMW-HA-
mediated down-regulation of RANKL, ST2 cells were pre-treated
with a Rho inhibitor (simvastatin) or selective Rho-associated
protein kinase (ROCK) inhibitor (Y27632) for 24 h prior to stimu-
lation with HMW-HA. Pretreatment with these inhibitors effec-
tively blocked the down-regulation of RANKLmRNA [Fig. 6(A)] and
RANKL protein [Fig. 6(B)] by HMW-HA.
HMW-HA inhibits osteoclast formation supported by ST2 cells
To determine whether HMW-HA has an inﬂuence ton ST2 cell-
supported osteoclast formation, cells were treated with
1,25(OH)2D3, which markedly stimulated Rankl mRNA expression
in the ST2 cells for up to 24 h, while the addition of HMW-HA
decreased the response of the cells to 1,25(OH)2D3 [Fig. 7(A)]. As
shown in [Fig. 7(B)], the level of RANKL protein expression was
increased in ST2 cells at 48 h after stimulation with 1,25(OH)2D3
and that stimulation was down-regulated by addition of HMW-HA.
Western blotting analysis also revealed that pre-treatment with the
Rho/ROCK inhibitors attenuated the down-regulation of RANKL
protein in 1,25(OH)2D3-stimulated ST2 cells mediated by HMW-HA.
To further clarify the role of the HMW-HA in osteoclastogenesis,
we cocultured mouse monocytes (RAW 264.7 cells), as osteoclast
precursors with ST2 cells pre-stimulated with 1,25(OH)2D3. As
shown in [Fig. 7(C) and (D)], culturing with HMW-HA down-Fig. 5. Effects of HMW-HA on RhoA activation in ST2 cells. (A) ST2 cells were incubated in t
cells were pretreated with or without 10 mg/ml CD44 mAb for 2 h, then incubated with HMW
blot analyses, with the blots probed for anti-RhoA (total RhoA). Equivalent protein aliquot
Rhotekin RBD, followed by SDS-PAGE and western blot analyses with the anti-RhoA antiboregulated the differentiation of RAW 264.7 cells into osteoclast-like
cells induced by 1,25(OH)2D3-stimulated ST2 cells.
Discussion
Bone resorption has been reported to be increased in women
with progressive knee OA as compared to those with non-
progressive disease34. Furthermore, peripheral blood mono-
nuclear cells from patients with OA have been shown to exhibit
enhanced capacity to generate osteoclasts and higher levels of bonehe presence or absence of 50 mg/ml of HMW-HA for the indicated time periods. (B) ST2
-HA (50 mg/ml) for 30 min. Whole cell lysates were subjected to SDS-PAGE and western
s of cell lysates were also analyzed for b-actin. GTP-RhoA was isolated utilizing GST-
dy.
Fig. 7. Effects of HMW-HA on osteoclast formation supported by ST2 cells. (A) ST2 cells were stimulated with 1,25(OH)2D3 (107 M) in the presence or absence of HMW-HA (50 mg/
ml) for the indicated times. Total RNAwas isolated and reverse transcribed into cDNA, then PCR ampliﬁcationwas performed using primers speciﬁc for Rankl and Gapdh. Data shows
the fold changes in Rankl mRNA copy number values from independent samples of n ¼ 3, and bars represent means with the standard deviation. Data were analyzed by Tukey’s
post-test after one-way ANOVA (P < 0.0001). The asterisk indicates P < 0.0001 in comparison to treatment with 1,25(OH)2D3. (B) ST2 cells were pretreated with simvastatin (10 mM)
or Y27632 (10 mM) for 24 h, then incubated with 1,25(OH)2D3 (107 M) in the presence or absence of HMW-HA (50 mg/ml) for 48 h. Whole cell lysates were subjected to SDS-PAGE
and western blotting analyses, with the blots probed for RANKL. Equivalent protein aliquots of cell lysates were also analyzed for b-actin. (C) ST2 cells were pre-treated with
1,25(OH)2D3 (107 M) in the presence or absence of HMW-HA (50 mg/ml) for 24 h, then co-cultured with RAW 264.7 cells for 6 days and stained for TRAP activity. Bars indicate
500 mm. (D) The number of osteoclast-like cells was counted after the staining for TRAP activity. Data shows the number of osteoclast-like cells from independent samples of n ¼ 3,
and bars represent means with the standard deviation. Data were analyzed by Tukey’s post-test after one-way ANOVA (P < 0.0001). The asterisk indicates P < 0.0001 in comparison
to treatment with 1,25(OH)2D3.
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bisphosphonate was found to prevent bone and cartilage resorp-
tion in a rat degenerative joint disease model36. Therefore, there is
great interest in identifying the effects of HMW-HA on osteoclas-
togenesis as a target for developing therapeutic agents to prevent
joint destruction in OA.
In the present study, we used a homogeneous clonal population
of mouse bone marrow stromal ST2 cells to elucidate the effects of
HMW-HA on induction of osteoclast differentiation. This cell line is
known to highly express RANKL in the presence of 1,25(OH)2D3 and
RANKL-expressing cells support the differentiation of splenic cells
into osteoclasts37. The main advantage of the present system is that
it does not contain any pre-osteoclast cells, which may also be
targets of HMW-HA activities.
As shown in Figs. 1 and 3, RANKL mRNA and protein were
decreased by addition of HMW-HA, indicating that it has protective
effects against osteoclastogenesis. Chang et al. reported that HMW-
HA (1,300 kDa) decreased osteoclast formation by bone marrow-
derived macrophages and human peripheral blood monocytic
cells, but not by RAW 264.7 cells25. In the study, they discussed that
the difference in effects of HMM-HA between RAW 264.7 cells and
primary osteoclast precursors may be ascribed to the independence
of RAW 264.7 cells on macrophage colony stimulating factor (M-
CSF) for proliferation and osteoclastic differentiation. Furthermore,
our results would suggest that suppression of osteoclastogenesis by
HMW-HA is also dependent on down-regulation of RANKL
expression in osteoblasts/stromal cells. In contrast to those ﬁnd-
ings, Cao et al. reported that HMW-HA stimulated RANKL expres-
sion in bone marrow stromal cells38. We have no ready explanationfor these contrasting results, though it is possible that they reﬂect
differences in the cell species tested or variations in culture con-
ditions, including the presence or absence of serum.
The modiﬁed coumarin, 4-MU has been reported to speciﬁcally
inhibit HA synthesis and pericellular HA matrix formation in
cultured mammalian cells29,30. Several studies have reported the
various biological effects of 4-MU on inﬂammatory response in
arthritis39, tumourigenicity40, and nerve injury41. As shown in
Figs. 2 and 3, we found that 4-MU up-regulated RANKL expression,
and our observations suggest that inhibition of HA synthesis and
loss of cellematrix interaction enhance osteoclast differentiation
and bone resorption. In addition, the effect of 4-MU on proliferation
of ST2 cells was examined using aWST-1 assay, though no effect on
cell growth up to 48 h was seen.
Another important ﬁnding of our study is that the HA receptor
CD44 is required for down-regulation of RANKL mediated by
HMW-HA. CD44 is one of the major HA binding proteins and
expressed in several types of cells, including osteoblasts42, while
binding of HA to CD44 is known to be involved in onset of a
variety of biological activities. The monoclonal rat anti-CD44
antibody recognizes a determinant of the HA binding region
common to CD44 and its principal variant isoforms43 and that
antibody is routinely used in HA-related blocking experiments. As
shown in [Fig. 4(A)], pre-treatment with that CD44 function-
blocking monoclonal antibody resulted in signiﬁcantly reduced
accumulation of exogenous HMW-HA in ST2 cells. We also found
that this antibody remarkably inhibited the effect of HMW-HA on
down-regulation of RANKL in ST2 cells [Fig. 4(B) and (C)]. On the
basis of these ﬁndings, we speculate that expression of CD44 in
W. Ariyoshi et al. / Osteoarthritis and Cartilage 22 (2014) 111e120118ST2 cells, which have the same lineage as osteoblasts, leads to
regulation of osteoclast formation and activation mediated by
HMW-HA.
Rho GTPases (RhoA, Rac1, Cdc42) are members of the Rho
subclass of the Ras superfamily44, and have a cycle between active
GTP-bound states and inactivate GDP-bound states in response to
external stimuli. In their active form, they regulate key signaling
pathways and control a variety of cellular activities, including
gene transcription, cytoskeleton reorganization, cell growth,
migration, and oncogenesis45. Previous studies have also found
that HA-CD44 binding induces RhoA signaling in head and neck
tumor cells46. In the present study, addition of HMW-HA led to a
signiﬁcant increase in the level of active GTP-bound RhoA
[Fig. 5(A)], while pre-treatment with the CD44 function-blocking
monoclonal antibody remarkably inhibited HMW-HA-induced
RhoA activation in ST2 cells [Fig. 5(B)]. These results demon-
strated that HA-CD44 interaction also induces RhoA signaling in
osteoblasts/stromal cells.
Recent ﬁndings indicate that the RhoA signaling pathway has
important roles in bone remodeling. For example, in osteoblast
survival31, the integrity of the actin cytoskeleton32, as well as
migration and differentiation33 are regulated by RhoA signaling.
Simvastatin has been reported to reduce the synthesis of mevalo-
nate by inhibiting hydroxymethylglutaryl (HMG)-CoA reductase,
ﬁnally leading to blockade of Rho GTPases by the effector proteins
ROCK47. On the other hand, Y-27632, a pyridine derivative, was
discovered to particularly disrupt ROCK signaling48 and has been
widely investigated in various studies. We found that blockage the
RhoA/ROCK pathway by either simvastatin or Y-27632 prevented a
decrease in RANKL expression caused by exposure to HMW-HA
[Fig. 6]. These ﬁndings are consistent with a previous study, in
which the expression of constitutively active RhoA in osteoblastic
cells was shown to impair their ability to induce osteoclastogenesis
via suppression of RANKL mRNA in response to parathyroid hor-
mone or calcitol.49
As a catabolic effect on bone, 1a,25(OH)2D3 promotes osteo-
clastogenesis by up-regulating the expression of RANKL. In the
present study, administration of HMW-HA decreased RANKL
expression induced by 1a,25(OH)2D3 [Fig. 7(A)], while simvastatin
and Y-27632 recovered that decreased expression in cells treated
with HMW-HA [Fig. 7(B)]. HMW-HA also prevented osteoclast
differentiation of co-cultured precursors supported by stromal cells
expressing RANKL [Fig. 7(C) and (D)]. These results suggest that
activation of RhoA/Rho kinase signaling by HMW-HA inhibits
RANKL in bone marrow stromal cells, thereby inhibiting osteo-
clastogenesis. Furthermore,1a,25(OH)2D3 was reported to suppress
the gene expression of osteoprotegerin (OPG), which acts as a decoy
receptor for RANKL and prevents RANKeRANKL interaction, and
thus osteoclastogenesis50. In our study, HMW-HA recovered up-
regulation of RANKL expression, while the down-regulation of
OPG was mediated by 1a,25(OH)2D3 (data not shown). Bone
resorption is a multistep process initiated by the proliferation of
immature osteoclast precursors, which is followed by the
commitment of those cells to the osteoclast phenotype and
degradation of the organic and inorganic phases of bone by mature
resorptive cells. We previously reported that TRAP positive multi-
nucleated cells differentiated from RAW 264.7 cells by RANKL are
capable of bone resorption using calcium phosphate substrate
coated slides26. From those results, the molecular mechanism for
the effect of HMW-HA on OPG expression and on osteoclast func-
tion are currently under investigation in our laboratory.
HA is known to be associated with several cell surface mole-
cules, such as CD44, receptor for hyaluronan-mediated motility
(RHAMM), toll-like receptor-4 (TLR4), and intercellular adhesion
molecule (ICAM-1). It has also been reported that RHAMM, TLR4,and ICAM-1 are expressed in osteoblast stromal lineage cells.
Further study is needed to examine the correlations between
HMW-HA and other receptors regarding inhibition of osteoclast
formation, as well as signal transduction during osteoclastogenesis.
In conclusion, the present ﬁndings showed that HMW-HA in-
hibits the transcription of RANKL in stromal cells by activating the
RhoA/Rho kinase pathways. CD44-mediated signaling supports this
activation and is likely critical for certain cell types, such as stromal
cells. Furthermore, our results suggest that stromal cells have a
capacity to sense changes in cell surface HA-CD44 interactions,
resulting in regulation of bone metabolism. Whether analogous
effect of HMW-HA on osteoclast occurs in human cells or in vivo
animal model remains to be determined. Nonetheless, we consider
that these results provide a basis to understand why HMW-HA is
effective when used as treatment for OA.
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